Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. more
Time Frame | CRIS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.47% | -3.35% | -2.97% |
1-Month Return | -19% | -3.49% | -0.66% |
3-Month Return | -48.23% | -12.6% | 2.71% |
6-Month Return | -61.43% | -6.91% | 7.21% |
1-Year Return | -74.54% | 1.19% | 23.04% |
3-Year Return | -96.85% | -0.21% | 28.43% |
5-Year Return | -89.97% | 33.09% | 82.88% |
10-Year Return | -97.38% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 10.00M | 10.84M | 10.65M | 10.16M | 10.02M | [{"date":"2019-12-31","value":92.33,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.28,"profit":true},{"date":"2022-12-31","value":93.79,"profit":true},{"date":"2023-12-31","value":92.51,"profit":true}] |
Cost of Revenue | 503.00K | 534.00K | 533.00K | 257.00K | 229.00K | [{"date":"2019-12-31","value":94.19,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.81,"profit":true},{"date":"2022-12-31","value":48.13,"profit":true},{"date":"2023-12-31","value":42.88,"profit":true}] |
Gross Profit | 9.50M | 10.30M | 10.12M | 9.90M | 10.02M | [{"date":"2019-12-31","value":92.23,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.2,"profit":true},{"date":"2022-12-31","value":96.16,"profit":true},{"date":"2023-12-31","value":97.3,"profit":true}] |
Gross Margin | 94.97% | 95.07% | 94.99% | 97.47% | 100.00% | [{"date":"2019-12-31","value":94.97,"profit":true},{"date":"2020-12-31","value":95.07,"profit":true},{"date":"2021-12-31","value":94.99,"profit":true},{"date":"2022-12-31","value":97.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 33.86M | 35.20M | 52.18M | 62.92M | 58.35M | [{"date":"2019-12-31","value":53.81,"profit":true},{"date":"2020-12-31","value":55.94,"profit":true},{"date":"2021-12-31","value":82.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.74,"profit":true}] |
Operating Income | (24.36M) | (24.90M) | (42.06M) | (53.02M) | (48.33M) | [{"date":"2019-12-31","value":-2435600000,"profit":false},{"date":"2020-12-31","value":-2489800000,"profit":false},{"date":"2021-12-31","value":-4206500000,"profit":false},{"date":"2022-12-31","value":-5302000000,"profit":false},{"date":"2023-12-31","value":-4833200000,"profit":false}] |
Total Non-Operating Income/Expense | (12.02M) | (10.04M) | (7.63M) | (7.30M) | (1.04M) | [{"date":"2019-12-31","value":-1201700000,"profit":false},{"date":"2020-12-31","value":-1004200000,"profit":false},{"date":"2021-12-31","value":-763200000,"profit":false},{"date":"2022-12-31","value":-730400000,"profit":false},{"date":"2023-12-31","value":-103700000,"profit":false}] |
Pre-Tax Income | (32.14M) | (29.91M) | (45.44M) | (56.67M) | (47.41M) | [{"date":"2019-12-31","value":-3214100000,"profit":false},{"date":"2020-12-31","value":-2990800000,"profit":false},{"date":"2021-12-31","value":-4543600000,"profit":false},{"date":"2022-12-31","value":-5667200000,"profit":false},{"date":"2023-12-31","value":-4741300000,"profit":false}] |
Income Taxes | 4.66M | 4.97M | 5.20M | 3.65M | (255.00K) | [{"date":"2019-12-31","value":89.6,"profit":true},{"date":"2020-12-31","value":95.56,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.18,"profit":true},{"date":"2023-12-31","value":-4.9,"profit":false}] |
Income After Taxes | (36.80M) | (34.88M) | (50.64M) | (60.32M) | (47.16M) | [{"date":"2019-12-31","value":-3680400000,"profit":false},{"date":"2020-12-31","value":-3488100000,"profit":false},{"date":"2021-12-31","value":-5064000000,"profit":false},{"date":"2022-12-31","value":-6032400000,"profit":false},{"date":"2023-12-31","value":-4715800000,"profit":false}] |
Income From Continuous Operations | (32.14M) | (29.91M) | (45.44M) | (56.67M) | (47.03M) | [{"date":"2019-12-31","value":-3214100000,"profit":false},{"date":"2020-12-31","value":-2990800000,"profit":false},{"date":"2021-12-31","value":-4543600000,"profit":false},{"date":"2022-12-31","value":-5667200000,"profit":false},{"date":"2023-12-31","value":-4703000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (36.80M) | (34.88M) | (50.64M) | (60.32M) | (47.41M) | [{"date":"2019-12-31","value":-3680400000,"profit":false},{"date":"2020-12-31","value":-3488100000,"profit":false},{"date":"2021-12-31","value":-5064000000,"profit":false},{"date":"2022-12-31","value":-6032400000,"profit":false},{"date":"2023-12-31","value":-4741300000,"profit":false}] |
EPS (Diluted) | (19.40) | (0.67) | (0.50) | (0.61) | (4.40) | [{"date":"2019-12-31","value":-1940,"profit":false},{"date":"2020-12-31","value":-67,"profit":false},{"date":"2021-12-31","value":-50,"profit":false},{"date":"2022-12-31","value":-61,"profit":false},{"date":"2023-12-31","value":-440,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CRIS | |
---|---|
Cash Ratio | 0.95 |
Current Ratio | 1.22 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CRIS | |
---|---|
ROA (LTM) | -45.97% |
ROE (LTM) | -372.68% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CRIS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.21 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.21 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CRIS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2.68 |
P/B | 4.32 |
Price/FCF | NM |
EV/R | 1.13 |
EV/Ebitda | 0.56 |
PEG | NM |
Curis Inc (CRIS) share price today is $3.07
Yes, Indians can buy shares of Curis Inc (CRIS) on Vested. To buy Curis Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRIS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Curis Inc (CRIS) via the Vested app. You can start investing in Curis Inc (CRIS) with a minimum investment of $1.
You can invest in shares of Curis Inc (CRIS) via Vested in three simple steps:
The 52-week high price of Curis Inc (CRIS) is $17.49. The 52-week low price of Curis Inc (CRIS) is $3.05.
The price-to-earnings (P/E) ratio of Curis Inc (CRIS) is
The price-to-book (P/B) ratio of Curis Inc (CRIS) is 4.32
The dividend yield of Curis Inc (CRIS) is 0.00%
The market capitalization of Curis Inc (CRIS) is $27.26M
The stock symbol (or ticker) of Curis Inc is CRIS